Drug Search Results
More Filters [+]

PRO-122

Alternative Names: pro-122, pro122, pro 122
Latest Update: 2023-12-12
Latest Update Note: Clinical Trial Update

Product Description

Laboratorios Sophia S.A de C.V. is developing pro-122, a topical ADRB2 Antagonist,ADRA2A Agonist,CA Inhibitor for Glaucoma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03966365)

Mechanisms of Action: ADRB2 Antagonist,ADRA2A Agonist,CA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Laboratorios Sophia S.A de C.V.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PRO-122

Countries in Clinic: Colombia, Mexico

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Glaucoma, Open-Angle

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PRO-122LATAM

P3

Recruiting

Glaucoma, Open-Angle

2024-06-30

95%

Recent News Events